Additionally, targeting NB via L1CAM with the application of a chimeric antigen receptor (CAR) that contains the scFv (i.e., single-chain fragment variable) of the CE7 mAb to modify T cells for adoptive immunotherapy is currently being developed [178]. Here, L1CAM is linked to neuroblastoma.